Product name: Spicatine A
Synonym name: 8-O-Ethylbenzoylaconine；8-O-Ethyl-14-benzoylaconine
Catalogue No.: BP5200
Cas No.: 124256-81-1
Formula: C₃₄H₄₉NO₁₀
Mol Weight: 631.763
Botanical Source: Aconitum carmichaelii Debx.
Type of Compound: Alkaloids

Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle

Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.

The product could be supplied from milligrams to grams
Inquire for bulk scale.

For Reference Standard and R&D, Not for Human Use Directly.

Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃

Introduction/Overview

8-O-ethyl-14-benzoyl Spicatine A (CAS No.: 124256-81-1) is a natural alkaloid derived from Aconitum plants. In recent years, it has attracted widespread attention in the pharmacological community due to its remarkable analgesic activity. As a complex alkaloid derivative, Spicatine A holds certain medicinal value in traditional Chinese medicinal materials, with its unique chemical structure giving it the potential for multi-target action. Analgesia, as a common and complex clinical treatment need, involves regulation of multiple receptors and pathways. Natural products, due to their structural diversity and bioactive complexity, have become important resources for the development of novel analgesic drugs. This paper systematically reviews the chemical structure and physicochemical properties of Spicatine A, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation, and pharmacokinetic characteristics, and looks ahead to its clinical application potential, aiming to provide theoretical basis and reference for in-depth research and drug development of this natural product.

Chemical structure and physicochemical properties

Spicatine A is an alkaloid with a complex polycyclic structure, with a molecular weight of 631.7630 and a complex formula, containing multiple aromatic rings and ester groups. Its chemical name, "8-O-ethyl-14-benzoylaconitobase," reflects the key ethyl and benzoyl modification groups in its molecule. These structural modifications not only affect its molecular hydrophobicity and polarity but also play a decisive role in its binding affinity with biological targets.

In terms of physicochemical properties, Spicatine A has a LogP value of 2.2721, indicating moderate lipid solubility, which facilitates cell membrane penetration without excessive hydrophobicity that reduces bioavailability. Its polar surface area (TPSA) is 136.38 Ų, indicating that the molecule has a relatively high polarity region that may affect its transmembrane transport and receptor binding. Its low water solubility (0.1808 mg/mL) limits its solubility in the aqueous phase, suggesting that strategies to improve solubility should be considered in drug formulation design. The blood-brain barrier has low permeability, suggesting that its direct central nervous system effect may be limited, but it is more likely to exert analgesic effects through peripheral targets. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. The Ames test value was 0.3, indicating a low genotoxicity risk and meeting safety requirements.

Plant Origins and Extraction Methods

Spicatine A mainly comes from plants of the genus Aconitum (Aconitum spp.), and is especially abundant in certain traditional Chinese medicinal materials such as Chuanwu and Caowu. Aconite plants are widely distributed in temperate and subtropical regions of Asia and have long been used to treat rheumatic pain, neuralgia, and other diseases. Due to its complex and limited alkaloid composition, extraction and separation processes are crucial for obtaining high-purity Spicatine A.

Common extraction methods include solvent extraction and liquid-liquid separation, with ethanol or methanol typically used as extraction solvents to ensure sufficient alkaloid dissolution. After concentration, the extract is removed by acid-base adjustment methods, followed by separation and purification by column chromatography (such as silica gel columns, C18 reversed-phase columns) and high-performance liquid chromatography (HPLC) technology. In recent years, the application of ultrasound-assisted extraction and microwave-assisted extraction technologies has improved extraction efficiency and purity, reducing solvent usage and extraction time. Additionally, the extract is structured by combining mass spectrometry and nuclear magnetic resonance (NMR) technology to ensure accurate separation and identification of Spicatine A.

Pharmacological activity research

Spicatine A, as a natural alkaloid, exhibits significant analgesic activity, mainly achieved through multi-target regulation. Both in vitro and in vivo experiments have confirmed its alleviating effects on various pain models, including inflammatory pain, neuropathic pain, and pain caused by mechanical stimuli.

Research shows that Spicatine A can effectively inhibit the release of inflammatory mediators, reduce inflammatory responses, and thus alleviate inflammatory pain. Additionally, it demonstrates neuroprotective effects in neuropathic pain models, reducing hyperalgesia caused by nerve injury. In animal experiments, Spicatine A demonstrated good analgesic effects with few adverse reactions, indicating high safety and tolerability.

Compared to traditional opioid analgesics, Spicatine A works through the non-opioid receptor pathway, reducing the risk of addiction and resistance. Its multi-target mechanism gives it broader application potential in complex pain states.

Mechanism of action and molecular targets

The analgesic effects of Spicatine A involve various molecular targets, mainly including:

• TRPV1 (Transient Receptor Potential Vanillin Subtype 1): TRPV1 is a key ion channel in pain perception, involved in pain transmission caused by inflammation and thermal stimuli. Spicatine A can reduce the excitability of pain nerves by modulating TRPV1 activity, thereby exerting analgesic effects.

• CNR1 (Cannabinoid Receptor 1): As an important component of the endocannabinoid system, CNR1 plays a crucial role in pain regulation. Spicatine A may act as a regulator of CNR1, enhancing endogenous analgesia signals.

• OPRD1 (δ-opioid receptor), OPRM1 (μ-opioid receptor), OPRK1 (κ-opioid receptor): these opioid receptors are classic analgesic targets. Spicatine A has a certain affinity for these receptors and may relieve pain by activating or modulating opioid receptor signaling pathways.

• PTGS1 (cyclooxygenase-1) and PTGS2 (cyclooxygenase-2): These two enzymes catalyze the synthesis of prostaglandins and participate in inflammatory responses and pain transmission. Spicatine A inhibits PTGS1/2, reduces the production of inflammatory mediators, and exerts anti-inflammatory and analgesic effects.

• TRPA1 (Transient Receptor Potential Vanillin Subtype A1): The TRPA1 channel is involved in the perception of chemical stimuli and inflammatory pain. Spicatine A reduces pain sensation by modulating TRPA1 channel activity.

• SLC6A4 (serotonin transporter): The serotonin system plays an important role in central and peripheral pain regulation. Spicatine A may regulate serotonin levels and improve pain by affecting SLC6A4.

• DRD2 (Dopamine D2 receptor): The dopamine system is involved in emotional and cognitive regulation of pain. Spicatine A's action on DRD2 may help alleviate pain-related mood disorders.

In summary, Spicatine A regulates pain signal transduction and inflammatory responses through multi-target and multi-pathway synergistic effects, demonstrating a unique and complex analgesic mechanism.

Druggability evaluation and pharmacokinetics

From the perspective of druggability, Spicatine A exhibits relatively ideal drug properties. Its moderate molecular weight and LogP value comply with the Lipinski rule, facilitating oral drug absorption. A higher TPSA suggests greater polarity, which may limit some cell membrane penetration, but also aids in target selectivity. Low water solubility is a major challenge in formulation development, requiring improved bioavailability through technologies such as salt formation, nanocarriers, or liposomes.

The low permeability of the blood-brain barrier suggests that its analgesic effect is mainly achieved at the peripheral or spinal cord level, reducing the risk of central nervous system side effects. The inhibition of the hERG channel is negative and carries a low risk of genotoxicity, further supporting its safety.

Pharmacokinetic research is still in its early stages. Current data indicate that Spicatine A is metabolized stably in vivo, mainly through hepatic enzyme systems, with excretion primarily via bile and urine. Moderate half-life supports the design of daily dosing regimens. In the future, further studies on in vivo absorption, distribution, metabolism, and excretion (ADME) and toxicological evaluation are needed to improve its pharmacokinetic characteristics.

Prospects and outlooks for clinical applications

Given Spicatine A's significant analgesic activity and good safety across various pain models, it has broad clinical application prospects. Its multi-target mechanism of action offers new therapeutic approaches for refractory pain, especially in cases of opioid resistance or limited side effects, where Spicatine A may be an ideal candidate for alternative or adjuvant therapy.

Future research should focus on the following aspects:

1. Dosage form optimization and delivery routes: Enhancing water solubility and bioavailability, developing oral, topical, or injectable formulations to meet diverse clinical needs.

2. Systematic pharmacokinetics and toxicology studies: clarifying in vivo metabolic pathways, long-term safety, and potential toxicity.

3. Preclinical and clinical trials: Conduct multicenter, multi-phase clinical trials to verify efficacy and safety, and determine indication scope.

4. Combination drug studies: Exploring synergies with existing analgesics, reducing dosage and side effects.

5. In-depth analysis of molecular mechanisms: Using modern molecular biology techniques, we analyze their binding patterns to targets and signal regulation networks, guiding structural optimization and new drug design.

In summary, Spicatine A, as a promising natural analgesic, is expected to play an important role in pain management in the future.

Conclusion

8-O-ethyl-14-benzoyl aconitoine (Spicatine A), with its unique chemical structure and multi-target analgesic mechanism, demonstrates excellent pharmacological activity and safety. Its potential in pain treatment has attracted widespread attention, especially in the context of current challenges of resistance and side effects for analgesics. Through systematic chemical, pharmacological, and druggability studies, Spicatine A provides a valuable research example for natural product pharmacology and the development of novel analgesics. In the future, combining modern drug development technologies with clinical validation is expected to promote its clinical translation and benefit more pain patients.